Vor Biopharma Inc. - Common Stock (VOR)
0.1513
-0.0087 (-5.44%)
NASDAQ · Last Trade: May 10th, 12:12 AM EDT
Detailed Quote
Previous Close | 0.1600 |
---|---|
Open | 0.1600 |
Bid | 0.1559 |
Ask | 0.1560 |
Day's Range | 0.1311 - 0.1630 |
52 Week Range | 0.1311 - 1.870 |
Volume | 6,213,793 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,236,814 |
Chart
About Vor Biopharma Inc. - Common Stock (VOR)
Vor Biopharma Inc is a biotechnology company focused on developing innovative therapies for patients with cancer. The company is pioneering a unique approach to create engineered cell therapies that harness the power of the immune system to target and destroy cancer cells more effectively. By utilizing its proprietary platform, Vor Biopharma is working to enhance the safety and efficacy of these treatments, aiming to improve outcomes for patients suffering from various malignancies. The company is dedicated to advancing its research and development efforts to bring new hope and solutions to the oncology landscape. Read More
News & Press Releases
Via Benzinga · May 9, 2025
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · May 8, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.
Via Chartmill · May 8, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · May 8, 2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.
By Vor Biopharma · Via GlobeNewswire · May 8, 2025
CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.
By Vor Biopharma · Via GlobeNewswire · March 20, 2025

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.
By Vor Biopharma · Via GlobeNewswire · February 3, 2025

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman’s investment fund.
By Vor Biopharma · Via GlobeNewswire · January 8, 2025

Via Benzinga · December 27, 2024

Vor shares are higher lower on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing.
Via Benzinga · December 27, 2024

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025
By Vor Biopharma · Via GlobeNewswire · December 27, 2024

CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators.
By Vor Biopharma · Via GlobeNewswire · December 9, 2024

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host 1x1 investor meetings at the Stifel 2024 Healthcare Conference.
By Vor Biopharma · Via GlobeNewswire · November 12, 2024

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update.
By Vor Biopharma · Via GlobeNewswire · November 7, 2024

Via Benzinga · September 30, 2024

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company’s President and Chief Executive Officer, Dr. Robert Ang.
By Vor Biopharma · Via GlobeNewswire · September 30, 2024

Via Benzinga · September 10, 2024

Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions.
Via Benzinga · September 6, 2024

Via Benzinga · September 6, 2024

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.
By Vor Biopharma · Via GlobeNewswire · September 5, 2024

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
By Vor Biopharma · Via GlobeNewswire · August 28, 2024

VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024